Adherence to low-risk lifestyle habits combined with GLP-1 receptor agonist use was associated with a greater reduction in MACE risk than either approach alone, underscoring the importance of integrating lifestyle modification with pharmacotherapy in type 2 diabetes management.
The Lancet Diabetes & Endocrinology published a clinical update in Research Highlights on 25 Feb 2026.
The item focuses on Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study.
Review the original article for the full source wording and details.